Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by
Crossref.
King, Tamara
Rao, Srinivas
Vanderah, Todd
Chen, Qingmin
Vardanyan, Anna
and
Porreca, Frank
2006.
Differential Blockade of Nerve Injury–Induced Shift in Weight Bearing and Thermal and Tactile Hypersensitivity by Milnacipran.
The Journal of Pain,
Vol. 7,
Issue. 7,
p.
513.
HAINER, VOJTECH
KABRNOVA, KAROLINA
ALDHOON, BASHAR
KUNESOVA, MARIE
and
WAGENKNECHT, MARTIN
2006.
Serotonin and Norepinephrine Reuptake Inhibition and Eating Behavior.
Annals of the New York Academy of Sciences,
Vol. 1083,
Issue. 1,
p.
252.
Thase, Michael E.
Clayton, Anita H.
Haight, Barbara R.
Thompson, April H.
Modell, Jack G.
and
Johnston, J. Andrew
2006.
A Double-blind Comparison Between Bupropion XL and Venlafaxine XR.
Journal of Clinical Psychopharmacology,
Vol. 26,
Issue. 5,
p.
482.
Ramadan, Nabih M.
and
Buchanan, Thomas M.
2006.
New and future migraine therapy.
Pharmacology & Therapeutics,
Vol. 112,
Issue. 1,
p.
199.
Kim, H. Florence
and
Fisch, Michael J.
2006.
Antidepressant use in ambulatory cancer patients.
Current Oncology Reports,
Vol. 8,
Issue. 4,
p.
275.
Montgomery, Stuart
2006.
Serotonin noradrenaline reuptake inhibitors: Logical evolution of antidepressant development.
International Journal of Psychiatry in Clinical Practice,
Vol. 10,
Issue. sup2,
p.
5.
Baghai, Thomas C.
Volz, Hans-Peter
and
Möller, Hans-Jürgen
2006.
Drug treatment of depression in the 2000s: an overview of achievements in the last 10 years and future possibilities.
The World Journal of Biological Psychiatry,
Vol. 7,
Issue. 4,
p.
198.
Deecher, Darlene C.
Beyer, Chad E.
Johnston, Grace
Bray, Jenifer
Shah, S.
Abou-Gharbia, M.
and
Andree, Terrance H.
2006.
Desvenlafaxine Succinate: A New Serotonin and Norepinephrine Reuptake Inhibitor.
Journal of Pharmacology and Experimental Therapeutics,
Vol. 318,
Issue. 2,
p.
657.
Pakalapati, Ravi K
Bolisetty, Srinivas
Austin, Marie‐Paule
and
Oei, Julee
2006.
Neonatal seizures from in utero venlafaxine exposure.
Journal of Paediatrics and Child Health,
Vol. 42,
Issue. 11,
p.
737.
Schwartz, Thomas L
and
Nihalani, Nikhil
2006.
Tiagabine in anxiety disorders.
Expert Opinion on Pharmacotherapy,
Vol. 7,
Issue. 14,
p.
1977.
McAllister-Williams, R Hamish
2006.
Duloxetine in the management of depression.
Future Neurology,
Vol. 1,
Issue. 6,
p.
713.
Rosenzweig-Lipson, Sharon
Beyer, Chad E.
Hughes, Zoë A.
Khawaja, Xavier
Rajarao, Somana J.
Malberg, Jessica E.
Rahman, Zia
Ring, Robert H.
and
Schechter, Lee E.
2007.
Differentiating antidepressants of the future: Efficacy and safety.
Pharmacology & Therapeutics,
Vol. 113,
Issue. 1,
p.
134.
Zhang, Lu
Chappell, Jill
Gonzales, Celedon R
Small, David
Knadler, Mary P
Callaghan, JT
Francis, Jennie L
Desaiah, Durisala
Leibowitz, Mark
Ereshefsky, Larry
Hoelscher, David
Leese, Philip T
and
Derby, Michael
2007.
QT Effects of Duloxetine at Supratherapeutic Doses: A Placebo and Positive Controlled Study.
Journal of Cardiovascular Pharmacology,
Vol. 49,
Issue. 3,
p.
146.
Lennestål, Roland
and
Källén, Bengt
2007.
Delivery Outcome in Relation to Maternal Use of Some Recently Introduced Antidepressants.
Journal of Clinical Psychopharmacology,
Vol. 27,
Issue. 6,
p.
607.
Stahl, Stephen M.
Ahmed, Saeeduddin
and
Haudiquet, Vincent
2007.
Analysis of the Rate of Improvement of Specific Psychic and Somatic Symptoms of General Anxiety Disorder During Long-Term Treatment with Venlafaxine ER.
CNS Spectrums,
Vol. 12,
Issue. 9,
p.
703.
Millet, B.
2007.
Apport des ISRS et IRSNA dans l’anxiodépression.
L'Encéphale,
Vol. 33,
Issue. 4,
p.
699.
Millan, Mark J.
and
Dekeyne, Anne
2007.
Discriminative stimulus properties of the selective norepinephrine reuptake inhibitor, reboxetine, in rats: a characterization with α/β-adrenoceptor subtype selective ligands, antidepressants, and antagonists at neuropeptide receptors.
The International Journal of Neuropsychopharmacology,
Vol. 10,
Issue. 05,
Roggen, Heidi
Kehler, Jan
Stensbøl, Tine Bryan
and
Hansen, Tore
2007.
Synthesis of enantiomerically pure milnacipran analogs and inhibition of dopamine, serotonin, and norepinephrine transporters.
Bioorganic & Medicinal Chemistry Letters,
Vol. 17,
Issue. 10,
p.
2834.
Hartford, James
Kornstein, Susan
Liebowitz, Michael
Pigott, Teresa
Russell, James
Detke, Michael
Walker, Daniel
Ball, Susan
Dunayevich, Eduardo
Dinkel, Jeff
and
Erickson, Janelle
2007.
Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial.
International Clinical Psychopharmacology,
Vol. 22,
Issue. 3,
p.
167.
Bradesi, Sylvie
and
Mayer, Emeran A
2007.
Novel therapeutic approaches in IBS.
Current Opinion in Pharmacology,
Vol. 7,
Issue. 6,
p.
598.